Nebkliq (Amlodipine Besilate, Nebivolol Hydrochloride)

Nebkliq combines a calcium‑channel blocker and a beta‑blocker to manage elevated blood pressure.

• Hypertension: lowers systolic and diastolic blood pressure in adults with primary hypertension.
• Isolated systolic hypertension: reduces elevated systolic pressure when diastolic values are normal.
• Diastolic hypertension: helps control high diastolic pressure in patients with isolated diastolic elevation.

• Amlodipine besilate blocks L‑type calcium channels in vascular smooth muscle, preventing calcium influx and causing arterial vasodilation. Nebivolol hydrochloride selectively antagonizes β1‑adrenergic receptors, decreasing heart rate and myocardial contractility, while also stimulating endothelial nitric‑oxide release, which further promotes vasodilation and lowers blood pressure.

Nebkliq may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate headache may occur.
• Peripheral edema: swelling of the ankles or feet.
• Dizziness: sensation of light‑headedness, especially on standing.
• Fatigue: general tiredness or lack of energy.

Serious or Rare Side Effects

• Severe hypotension: markedly low blood pressure requiring medical attention.
• Bradycardia: abnormally slow heart rate.
• Angioedema: swelling of face, lips, tongue, or throat.
• Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating Nebkliq, clinicians should consider several safety measures.

• Monitor blood pressure: ensure adequate control and avoid excessive drops.
• Assess cardiac function: evaluate heart rate and rhythm, especially in patients with conduction disorders.
• Review concomitant medications: watch for additive hypotensive effects.
• Use caution in hepatic impairment: dose adjustments may be needed.
• Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebkliq can interact with other medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Other antihypertensive agents (e.g., ACE inhibitors, ARBs): risk of excessive blood pressure reduction.
• Non‑dihydropyridine calcium‑channel blockers (e.g., verapamil, diltiazem): may cause pronounced bradycardia.

Moderate Interactions (Monitor Closely)

• Diuretics: can enhance the hypotensive effect.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower drug exposure and reduce efficacy.